Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Kaposi 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Graft vs Host Disease 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Valganciclovir 3Paclitaxel 3Nelfinavir 3Bevacizumab 3pembrolizumab 2Zidovudine 2Semaxinib 2Ritonavir 2Propranolol 2Nivolumab 2Interferon alpha-2 2Indinavir 2Filgrastim 2Etoposide 2Doxorubicin 2vesnarinone 1tocilizumab 1tin etiopurpurin 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1talimogene laherparepvec 1nirogacestat 1liposomal doxorubicin 1lenvatinib 1ixazomib 1halofuginone 1etoposide phosphate 1daromun 1Vincristine 1Sunitinib 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Sarcoma, Kaposi × Maraviroc × Clear all
NCT01276236 2021-03-05

Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)

University of California, San Francisco

Phase 2 Completed
13 enrolled 16 charts
Sarcoma

Sarcoma, Kaposi

Data powered by HemOnc (CC BY 4.0) Colophon âš¡